IPO Review: Glenmark Life Sciences Ltd
Moneylife Digital Team 28 July 2021
Glenmark Life Sciences Ltd (GLSL) is a developer and manufacturer of active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. It has a strong market share in...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
Already a subscriber ? Log in
Free Helpline
Legal Credit